Acute Renal effects of Angiotensin II Management In Shock in the Intensive Care Unit (ARAMIS-ICU)

Phase 2

Completed

• Conditions: Distributive shock; Renal and Urogenital - Kidney disease; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12621000281897
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-12
• Study Completion: 2021-07-27
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

•Adults aged > 18 years
•Vasodilatory shock (MAP <65 mmHg)
•Central venous access and an arterial line present
•Indwelling urinary catheter
•Expected to require vasopressor support for at least 24 hours
•Informed consent provided by the patient or medical treatment decision-maker

Exclusion Criteria

•Cardiac surgery patients
•>24 hours noradrenaline or metaraminol prior to enrolment
•Chronic haemodialysis or peritoneal dialysis
•Not receiving venous thromboembolism prophylaxis
•Venous thromboembolism or pulmonary embolus in the last 6 months
•Expected survival <24 hours
•Suspected or confirmed pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified